Abstract
Alcohol-associated liver disease has become the most common reason for liver transplantation (LT) in many regions, including the US. This shift reflects the declining hepatitis C-related LTs and rising prevalence of harmful alcohol use, which increased substantially, especially during COVID-19 pandemic. Post-LT alcohol relapse leads to poor clinical outcomes, including medication non-adherence, graft dysfunction (steatosis and alcohol-related hepatitis), recurrent cirrhosis, and decreased overall survival. For patients with severe alcohol-associated hepatitis, early or expedited LT can offer a survival advantage in carefully selected candidates compared with traditional approaches requiring six months of pre-LT abstinence, without a substantial increase in hazardous relapse. Pre-LT risk assessment is essential for the candidate selection and combines psychosocial factors with validated tools such as Stanford Integrated Psychosocial Assessment for Transplantation, Hopkins psychosocial scale, sustained alcohol use post-LT, harmful alcohol use post-LT, and high-risk alcoholism relapse. Post-LT monitoring utilizing direct biomarkers (e.g., phosphatidylethanol, ethyl glucuronide) with indirect markers of alcohol-use to widen the detection window and capture both low-level and heavy use should be considered. Optimal management of alcohol-use disorder (AUD) relies on combining pharmacologic and psychosocial interventions. Among pharmacologic options, naltrexone and acamprosate are considered first-line options, whereas disulfiram is less commonly used after LT given concerns about its drug interactions. Psychosocial aspects of the management are as important as the pharmacologic aspects to maintain abstinence and reduce relapse risk. Potential barriers to participation, such as hepatic decompensation, hepatic encephalopathy, or logistical challenges, should also be recognized and addressed. This narrative review summarizes current management strategies for AUD with emphasis on the post-LT setting.
Keywords: Alcohol-related hepatitis, alcohol-use disorder, liver transplantation, relapse after liver transplant
Points to Note
Synthesis of Current Evidence: Alcohol relapse after liver transplantation worsens graft and patient outcomes; prevention requires pre-LT risk assessment, biomarker-based monitoring, and combined pharmacologic and psychosocial care.
Major Controversies: The 6-month abstinence rule, relapse definitions, and early LT for severe alcohol-associated hepatitis remain debated.
Future Directions: Standardized relapse criteria, validated risk tools, multicenter studies, and transplant-specific trials of AUD therapies are needed.
Introduction
Alcohol-associated liver disease (ALD) has become the most common reason for liver transplantation (LT) in many regions.[1,2] This shift reflects the widespread adoption of antiviral therapies that have markedly reduced hepatitis C virus-related transplant demand, as well as an increase in harmful alcohol consumption, which particularly escalated during the COVID-19 pandemic.[3] Data provided by Nielsen National Consumer Panel demonstrates substantial growth, 34%, in retail alcohol sales during the pandemic.[4] This surge in alcohol consumption led to the increased prevalence of alcohol use disorder (AUD), and ultimately, to a rise in ALD and LT waiting list addition.[5,6] AUD is defined as a chronic disease of unhealthy alcohol use despite adverse social, occupational, or health consequences.[7] ALD comprises a continuum of liver injury, evolving from steatosis to steatohepatitis and ultimately cirrhosis.[8] For selected patients with advanced ALD, LT remains the only therapeutic option. However, due to the standard 6-month abstinence rule implemented by most LT programs, many patients die before qualifying for a LT. This is reflected by the high mortality rate of 70% at 6 months in those unresponsive to corticosteroid treatment who would have otherwise benefited from a liver transplant.[9] Data show that deaths specifically linked to alcohol in the US increased by 25% from 2019 to 2020, while deaths attributed explicitly to ALD increased by about 22.4% during the same period.[3]
Because available donor organs remain limited and allocation carries ethical implications, transplant programs must carefully evaluate candidates with ALD to determine which individuals are most likely to remain abstinent following LT, thereby reducing the likelihood of recurrent alcohol use, associated complications, and ultimately graft loss. The pandemic-era spike in alcohol use further amplifies the relapse risk in the already vulnerable transplant recipient population. A critical challenge is how to prevent alcohol relapse in a post-pandemic world where access, stressors, and societal norms have changed.
Materials and Methods
A thorough literature review was conducted to gather relevant information for this narrative review of the prevention of AR in post-liver transplant patients with AUD. The search strategy included a combination of keywords related to post-transplant AR, its clinical impact, monitoring, prevention, and treatment. English-language studies published between 2000 and 2025 were identified through electronic databases including PubMed/MEDLINE, Embase, and Google Scholar. Titles and abstracts were screened initially for relevance, followed by pertinent sections of the body and full-text review of relevant articles. We included English literature publications coming from experienced institutions, as well as high-volume liver transplant centers, and also incorporated the authors’ clinical experience from their routine practice. We prioritized recent clinical practice guidelines, systematic reviews/meta-analyses, randomized trials when available, and large transplant cohort studies.
Clinical Impact of Relapse in Transplantation
AR after LT is associated with many adverse outcomes, including medication non-adherence, histopathological changes such as steatosis, steatohepatitis, and advanced fibrosis, as well as shortened survival after LT.[10,11] Graft steatosis and alcohol-associated hepatitis (AH) were found to be increased by four- to ninefold in patients who have AR.[12] These changes can lead to graft cirrhosis, graft loss, and ultimately patient mortality. At present, there is no standard definition for AR. This poses several significant challenges and undermines the consistency of clinical care. A major challenge is the clinical ambiguity, the policy, and the ethical implications. Since many LT programs often use AR as a criterion for listing or delisting patients, without a clear, shared definition, this process can become arbitrary or biased, raising concerns about fairness and equity.[13] In addition, the lack of consensus leads to inconsistent assessments and management strategies among providers, complicating eligibility decisions for LT and post-transplant care.[14] Therefore, to improve patient management and care, a classification system consisting of three AR categories was proposed:[8] (1) Mild relapse, referring to infrequent episodes of alcohol use, typically under once monthly; (2) moderate relapse, characterized by ongoing alcohol consumption that falls within drinking quantities considered acceptable by the National Institute on Alcohol Abuse and Alcoholism (NIAAA, generally no more than 4 daily or 14 weekly drinks for men, and 3 daily or 7 weekly drinks for women) and (3) severe relapse, marked by sustained intake exceeding NIAAA recommendations or accompanied by clinical complications such as pancreatitis, acute alcohol-related hepatitis, graft failure, or other medical consequences linked to resumed drinking. Per World Health Organization criteria, severe AR corresponds to self-reported consumption exceeding approximately 20 g daily in women or 30 g daily in men over a period of 6 months or longer.[15]
Of these three types of relapses, severe relapse carries the most significant risk as it can promptly result in recurrent alcohol-associated cirrhosis (RAC) in the transplanted liver.[16] RAC is one of the primary causes of mortality in transplanted patients with ALD, alongside de novo malignancies, and cardiovascular events.[17] Therefore, the selection of LT candidates with AUD is heavily influenced by their risk of AR after transplantation. AR can be predicted by multiple scoring systems, which will be discussed later. Utilizing these scoring systems and using the correct definitions of relapse is crucial in identifying patients at high-risk patients and implementing targeted follow-up programs to help prevent AR.
The Role of Early LT (ELT) in AH
Despite increasing acceptance, ELT practice still remains controversial. The traditional 6-month abstinence requirement has been questioned repeatedly, as several studies report comparable AR rates regardless of pre-transplant abstinence duration. ELT was first systematically described by Mathurin et al.,[18] who reported the data of LT for carefully selected patients with the first episode of severe AH (SAH) and <6 months of abstinence using strict psychosocial and medical criteria across seven centers in France and Belgium. In this cohort, patients unresponsive to medical therapy had an estimated 6-month survival of ~30% without LT, which improved to 77% among those who underwent ELT.[18] However, despite improved survival rates, ELT was associated with a higher incidence of post-LT alcohol use.[11] In contrast, a recent retrospective cohort study of 163 patients was evaluated for differences in 1-year overall survival, graft survival, and hazardous relapse–free survival. Hazardous relapse was further categorized into binge, at-risk, or frequent drinking. The study showed no significant difference in AR rates between patients who underwent ELT and those who underwent standard LT. Data showed a 1-year relapse-free survival in ELT as 80.4% versus standard LT as 83.5% (p=0.41), and the 1-year hazardous relapse–free survival in ELT as 85.8% versus standard LT as 89.6% (p=0.41). The only significant factor associated with worse survival was early relapse, referring to resumption of alcohol consumption within the first 90 days following transplantation, particularly with hazardous drinking patterns.[19] Another recent benchmark study did a retrospective chart review of 69 adults who underwent LT for ALD from 2018 to 2021, and AR rates did not differ between those who achieved 6 months of sobriety before LT and those who had not.[20] Although longer pre-LT sobriety correlated with reduced likelihood of AR, no definitive minimum abstinence period emerged as a reliable predictive threshold.[20]
Another concern raised in broader literature and the transplant community is whether ELT patients might have a higher risk of acute graft rejection. A meta-analysis study compared 228 ALD-associated LT patients in two groups: Those with fewer than 6 months of sobriety versus those exceeding 6 months. The main endpoint evaluated was the rate of biopsy-proven acute rejection (BPAR) during the 1st year after LT. They found that a sobriety duration under 6 months did not correlate with a higher incidence of BPAR in the first post-LT year,[21] indicating that ELT does not increase the risk of immune-mediated graft rejection. Therefore, given the consistent evidence from multiple studies showing that achieving a 6-month sobriety period does not meaningfully alter the likelihood of AR after LT or improve overall survival, ELT may be considered a reasonable option for carefully selected patients with severe ALD, within appropriate ethical and institutional frameworks and guided by the factors discussed in the following sections. It should also be noted that ELT practices vary by region and center due to differences in organ availability, regulatory context, addiction-care resources, and sociocultural norms. Ongoing ethical considerations include equitable access, transparent selection criteria, and consistent post-transplant support; policies should therefore be tailored locally and periodically reassessed.
Strategies for Preventing AR Post-Liver Transplant
Pre-Transplant Interventions
To improve clinical outcomes in patients undergoing LT for ALD, management efforts to prevent AR in the post-LT period should be initiated well in advance of the transplant procedure.
Managing Alcohol Withdrawal
Participation in an alcohol abstinence program, such as Alcoholics Anonymous (AA), is usually mandated by most LT centers. These programs assist patients in achieving and sustaining sobriety using psychosocial support and teaching patients how to cope with emotional stressors, triggers, and the mental hurdles of addiction. However, it is important to realize the challenges that come with abstinence in AUD and to address them. Withdrawal is a major event that can challenge a patient’s progress and recovery. Alcohol withdrawal syndrome (AWS) has been shown to occur to some degree in about 50% of patients with chronic excessive alcohol use after abrupt cessation or significant reduction of alcohol intake.[22] AWS typically begins within 1–3 days of admission and lasts for about 5 days.[23] One study on the relationship of pre-LT AWS and post-LT relapse showed that patients with pre-LT AWS had a significantly higher risk of post-LT relapse (subdistribution hazard ratio =6.37; 95% confidence interval 1.33–30.62; p=0.02).[24] Moreover, this study reported AWS to confirm the severity of AUD, and suggests that future evaluations should place greater emphasis on DSM-5 diagnostic standards and detailed alcohol-use histories to better identify risk factors for AR.[24]
Predicting Risk of AR
Predicting the risk of patient AR post-LT is the most crucial step in pre-LT evaluation. After identifying a medically appropriate candidate for LT, identifying their risk for AR is the next step. Categorizing patients as high or low risk is crucial for establishing close monitoring, support, and immediate intervention to prevent graft injury and loss. Several risk factors have been identified as being associated with the post-LT AR risk. A retrospective study showed that factors like being younger at LT, a history of AR, notable psychiatric disorders, alcohol consumption after cirrhosis was diagnosed, a shorter sobriety period before listing for LT, and participation in prior substance use treatment programs were statistically significant in association with AR.[20] Other studies showed coexisting psychiatric disorders, such as anxiety, depression, or personality-related conditions, were likewise linked to an increased risk of AR.[25,26] Risk prediction models and scoring systems are other important tools that can be used.
The Stanford integrated psychosocial assessment for transplantation (SIPAT) was first published in 2012. It assesses 4 categories: readiness and illness self-management, quality of social support, psychosocial stability and psychiatric status, and lifestyle factors including substance use. It assigns patients scores from 0 to 110, with higher scores indicating a higher psychosocial risk for AR. However, it was later found in a validation study that it demonstrated only moderate ability to predict overall psychosocial outcomes.[27]
The Hopkins psychosocial scale (HPSS) is a model that integrates factors specific to patients with AH along with recognized predictors of AR. An HPSS score <0 predicts sustained AR, which is derived based on the balance of protective versus high-risk factors. Protective factors contributing to the score include voluntary hospital presentation, pre-sobriety daily alcohol consumption, awareness of illness, duration of sobriety before LT, and marital status.[28]
The sustained alcohol use post-LT (SALT) score is a risk stratification tool, which integrates four variables to identify low-risk patients and has a score range of 0–11. These are: more than ten drinks per day at the initial admission (+4), a history of multiple rehabilitation attempts (+4), previous legal problems related to alcohol (+2), and past illicit substance abuse issues (+1 points). Per this scoring system, about 95% of those with a score under 5 remain abstinent of alcohol post-LT, while about 25% of those with a score of 5 or more continue drinking post-LT.[29]
The harmful alcohol use post-LT score is a multivariable regression-based model designed to estimate the likelihood of harmful alcohol use following LT. It incorporates age at the time of LT, history of non–alcohol-related legal offenses, duration of abstinence before LT, and average daily alcohol consumption.[30]
The high-risk alcoholism relapse (HRAR) scale predicts the risk of AR after LT in patients with ALD. It stratifies patients for more intensive follow-up or rehabilitation support; however, it does not account for factors like social support, mental health, or motivation to stay sober. Therefore, it is often used alongside other psychosocial evaluations like SIPAT. It is composed of three variables: Duration of heavy drinking, number of drinks per day, and number of prior inpatient treatments for alcoholism. An HRAR score of 4 or more indicated an increased risk for harmful alcohol use after LT.[25]
Notably, only the SALT and HPSS scores were designed specifically for patients undergoing ELT for SAH; however, neither has a consistent outcome measure or external validation.[31,32] Table 1 clarifies the relapse risk-prediction tools for specific clinical scenarios and patient subgroups briefly.
Table 1.
Scoring systems
| Scoring/Meaning of abbreviation | Target patient subgroups | The most suitable clinical scenario and timing |
|---|---|---|
| Hopkins Psychosocial Scale (HPSS) | HPSS predicts AR for individuals who are candidates of LT due to SAH. This scale benefits from unique factors specific for SAH patients additionally known risk factors for AR in AUD. | This scale is used in pre-transplant patient selection by classification in psychosocial assessment and considering ethical appropriateness. |
| Sustained alcohol use post-LT (SALT) | SALT predicts brief AR (“slip”) and sustained AR to alcohol usage in individuals receiving ELT for SAH. | This scale is used in pre-transplant period for post-transplant sustained alcohol usage prediction. |
| Harmful Alcohol use Post-Liver Transplant (HALT) | HALT is used in LT candidates with ALD or AH. | This scale is used in pre-transplant period for post-transplant harmful drinking risk prediction. |
| Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) | SIPAT, as a comprehensive psychosocial evaluation tool, predicts psychosocial consequences in individuals who are receiving solid organ transplant. This scale is nonspecific for AUD. | This scale is used in pre-transplant (in LT candidates with ALD) psychosocial assessment globally. |
| High-Risk Alcoholism Relapse (HRAR) (scale) | HRAR predicts AR and time of AR for individuals with AUD. In addition, this scale is nonspecific for organ transplantation. | This scale is used in relapse risk prediction in pre-transplant period (in LT candidates with ALD) by evaluating the addiction severity and AR related risk factors.[58] |
SAH: Severe alcohol-associated hepatitis; AR: Alcohol relapse; LT: Liver transplantation; AUD: Alcohol-use disorder; ELT: Early liver transplantation; AH: Alcohol-associated hepatitis; ALD: Alcohol-associated liver disease. Adapted from Dienstag et. al.59 with an additional column by the authors.
Post-Transplant Interventions
Monitoring and therapeutic approaches used to prevent post-LT AR are summarized in Figure 1 and further detailed in the following sections below.
Figure 1.

Overview of post-LT alcohol-relapse prevention strategies.
AA: Alcoholics anonymous; ALT: Alanine transaminase; AR: Alcohol relapse; AST: Aspartate transaminase; CBT: Cognitive behavioral therapy; CDT: Carbohydrate-deficient transferrin; EtG: Ethyl glucuronide; FDA: Food and drug administration; GGT: Gamma-glutamyl transferase; LT: Liver transplant; MCV: Mean corpuscular volume; MI: Motivational interviewing; NPV: Negative predictive value; PEth: Phosphatidylethanol; PPV: Positive predictive value.
Monitoring for Alcohol Use
Early detection of AR after LT cannot be overstated. As mentioned previously, post-LT AR is associated with many adverse outcomes that may lead to graft dysfunction. To prevent that, it is important for clinicians to have the tools to assess patients for alcohol intake and initiate intervention immediately. Random testing for alcohol through analysis of blood, urine, or breath samples continues to be the preferred method for detecting AR; however, its utility is limited by alcohol’s rapid metabolism and short detection window. Consequently, clinicians have increasingly relied on biochemical markers as more sensitive and specific tools for AR detection. These biomarkers are broadly classified into two categories: direct and indirect. Direct biomarkers are metabolites of alcohol, such as ethanol, phosphatidylethanol (PEth), and ethyl glucuronide (EtG), which specifically indicate recent alcohol consumption. PEth is a phospholipid that is formed only when phosphatidylcholine, a component of cell membranes, is metabolized by phospholipase D in the presence of ethanol. It can be detected in fresh whole blood or dry blood spots and is highly sensitive, capable of identifying even minimal alcohol consumption, as little as a single drink within the preceding 1–2 weeks.[33] In a cohort study, PEth was found to have a sensitivity of 100% and a specificity of 96% at a cut-off value of ≥20 ng/mL,[34] making it a reliable marker for the detection of alcohol use. On the other hand, indirect biomarkers reflect the physiological consequences of chronic alcohol use rather than alcohol itself. Common examples include aspartate transaminase/alanine transaminase ratio, gamma-glutamyl transpeptidase (GGT), mean corpuscular volume, and carbohydrate-deficient transferrin (CDT). These markers are practical and cost-effective screening tools for detecting heavy alcohol use; however, they lack sensitivity for identifying occasional lapses or minor drinking episodes.[32] Moreover, GGT and CDT can indicate alcohol use even in the absence of hepatitis; however, both may be elevated due to other causes such as hepatitis C infection, smoking, sepsis, or pulmonary diseases.[35] In comparison to indirect biomarkers, direct biomarkers represent the metabolic products of the non-oxidative pathways of ethanol metabolism and therefore demonstrate substantially higher specificity. Moreover, direct biomarkers have a substantially longer detection window, making them particularly valuable for confirming recent alcohol intake.[36] It was shown that combining both types achieved a positive predictive value of 89.3% and a negative predictive value of 98.9%.[37] Therefore, combining both direct and indirect biomarkers optimizes the detection of both chronic heavy drinking and low-level alcohol consumption.
Treatment of AR
Pharmacological Therapy
Medications for AUD (MAUD) play a key role in managing this condition as an additional treatment alongside psychosocial interventions.[7] Naltrexone, acamprosate, and disulfiram are currently the three FDA-approved medications for treating AUD. The effectiveness of these medications has been well established across multiple studies over recent years. Use of MAUD has been shown to reduce mortality and rehospitalization rates by 42%.[38] Despite the strong evidence, they are still surprisingly underused. Only 2% of the 30 million people with AUD are ever prescribed MAUD.[39] Their proven effectiveness supports wider use and integration into the management of appropriately selected post-LT patients with AUD. Similarly, direct comparative effectiveness data for MAUD in post–LT recipients are very limited. To date, no head-to-head trials have compared naltrexone, acamprosate, and baclofen specifically in post-LT populations, and the only randomized study in LT recipients is a recent pilot trial evaluating acamprosate versus standard of care without pharmacotherapy.[40]
Naltrexone is a μ-opioid receptor blocker that diminishes alcohol-induced reward signaling within the mesolimbic dopamine pathway, helping with the urge and craving to drink. However, the primary safety concern is its boxed warning, noting the risk of hepatocellular injury at high doses.[41] A new study investigated the use of an injectable extended-release naltrexone (XR-NTX) to overcome this adverse effect. A retrospective case series evaluated 14 adults with advanced ALD who received at least one 380 mg dose of XR-NTX between 2023 and March 2025. They concluded that none of these patients developed hepatotoxicity or hepatic decompensation and maintained stable liver function test results (MELD and Child-Pugh) throughout a minimum follow-up period of 12 weeks.[42]
Acamprosate is an N-methyl-D-aspartate (NMDA) receptor antagonist that attenuates the pleasurable effects of alcohol.[43] It was found to be a safe, feasible, and effective treatment with promising adherence and no signs of AR or liver-related complications for post-LT AUD patient.[40] It significantly increases cumulative abstinence duration and continuous abstinence rates compared with placebo.[44] In post-LT populations, comparative effectiveness data are extremely limited; nevertheless, acamprosate is the only MAUD formally studied in a randomized trial in LT recipients. In a recent pilot randomized trial (n=30), acamprosate 666 mg three times daily was safe and feasible over 14 weeks, with similar adverse event rates compared with standard of care (92.3% vs. 90.0%) and no grade 4/5 adverse events. No biochemical or reported AR occurred in either group; however, baseline craving scores were low, limiting conclusions regarding efficacy.[40] Its side effects are generally mild and dose-dependent, most commonly including transient diarrhea, while suicidal ideation has been reported rarely.[45] However, it is contraindicated in patients with severe renal impairment as it is renally eliminated.
Disulfiram is the first pharmacologic agent approved by the US Food and Drug Administration (FDA) for the treatment of AUD. Its pharmacologic effect is mediated through inhibition of aldehyde dehydrogenase, thereby disrupting alcohol metabolism and resulting in acetaldehyde accumulation. Acetaldehyde is the component that causes the aversive symptoms of drinking, like nausea, vomiting, hypotension, chest pain, and flushing. This negative reinforcement discourages patients from subsequent alcohol use. The main concern with this drug is acute liver injury. Aminotransferase elevation occurs in 25% of patients.[45] Because disulfiram is hepatically metabolized and moderately inhibits CYP 2C9, it carries a potential risk for significant drug-drug interactions with other agents metabolized by this pathway.[46] Therefore, disulfiram usage is limited in post-LT AUD patients.
Although Baclofen, a gamma-aminobutyric acid type B (GABA-B) receptor agonist, is not yet approved by FDA nor recommended by the American Psychiatric Association. Its effectiveness and safety as a potential pharmacotherapy are still being studied. A randomized clinical trial evaluated the effectiveness of baclofen to manage AUD. The 16-week study compared baclofen 30 and 90 mg/day versus placebo in 120 patients, examining the effects of dose, sex, and pretreatment drinking levels. The analysis demonstrated that baclofen treatment was associated with a reduction in heavy drinking and an increase in abstinent days. Specifically, baclofen resulted in 13.6 fewer heavy drinking days (p=0.018) and 12.9 more abstinent days (p=0.028) compared with placebo.[46] In addition to its role in the prevention of AR, baclofen also showed efficacy in managing AWS by activating GABA-B receptors and thereby effectively counterbalancing AWS-associated and NMDA-mediated glutamatergic excitatory neurotransmission.[47]
A comparative study evaluating pharmacotherapies for AUD showed that naltrexone produced the greatest reduction in alcohol craving and consumption, the lowest AR rate, but also the most adverse effects. On the other hand, baclofen exhibited the most favorable tolerability profile, with relatively stable liver function parameters and fewer reported adverse effects. The highest dropout rate was observed in the acamprosate group.[48]
In terms of transplant-specific considerations, no formal interaction studies between MAUD and immunosuppressants have been performed in LT recipients. Based on pharmacokinetics, clinically significant interactions appear unlikely for acamprosate (renal elimination, no hepatic metabolism), while naltrexone and baclofen also have no established interactions with calcineurin or mechanistic target of rapamycin inhibitors; however, evidence is limited, and vigilance is warranted. Accordingly, medication choice should be individualized with attention to renal function (acamprosate), hepatic injury monitoring (naltrexone), and sedation/neurocognitive risk (baclofen), with close follow-up.
GLP-1 receptor agonists (GLP-1RAs) are being explored as a potential adjunctive therapy for AUD. In a large VA EHR analysis, GLP-1RA exposure was associated with modest reductions in AUDs Identification Test-Consumption (AUDIT-C) scores compared with both propensity-score–matched unexposed patients and DPP-4 inhibitor users, with larger reductions observed among patients with baseline AUD.[49] In another VA EHR analysis of patients with harmful alcohol use, GLP-1RA exposure was associated with a lower risk of liver-related outcomes and mortality, as well as a lower likelihood of a positive AUDIT-C during follow-up.[50] Randomized evidence remains limited but encouraging: in a phase 2 trial in patients with AUD, weekly low-dose semaglutide reduced overall alcohol consumption and decreased drinks per drinking day and craving, without significant changes in overall drinking days in total. However, it should be noted that these data were generated while patients were under active surveillance.[51] Complementing these findings, a Swedish registry study reported a lower risk of AUD-related hospitalization during periods of semaglutide or liraglutide use compared with nonuse.[52] A recent systematic review and meta-analysis found heterogeneous, non-significant effects on alcohol consumption, but suggested fewer alcohol-related events and improved liver-related outcomes with GLP-1RA use.[53] Taken together, these findings are encouraging and support further studies to clarify the clinical effectiveness of GLP-1RAs for AUD and identify the patients most likely to benefit.
Behavioral Therapy
In conjunction with pharmacological therapy, behavioral therapy must be integrated into every patient’s management plan. Psychological interventions incorporate concepts from psychological theories, such as operant conditioning and cognitive theory, to disrupt AR loop. Cognitive behavioral therapy (CBT) is a behavior-focused approach that examines thought patterns to identify triggers that contribute to drinking and subsequently replaces maladaptive responses with alternative, non-drinking behaviors. CBT requires the patient’s active participation and sustained commitment, as it spans over 10 or more sessions. It is the most widely implemented behavioral intervention for AUD and is supported by robust evidence from randomized controlled trials and observational studies demonstrating its efficacy in promoting and maintaining abstinence.[54]
Motivational interviewing (MI) is another strategy. This technique emphasizes enhancing a patient’s internal awareness of the consequences of alcohol use. MI is guided by five principles: (1) demonstrating empathy to build connection; (2) highlighting discrepancies between patients’ goals and behaviors; (3) avoiding direct confrontation; (4) working collaboratively with, rather than opposing, resistance; and (5) reinforcing self-efficacy.[55]
Motivational enhancement (MET) uses the principles of MI but aims to evoke the patient’s intrinsic motivation for behavioral change.[56] In a study comparing patients who received MET with those who did not, MET was found to reduce both the quantity and frequency of pre-transplant alcohol consumption among LT candidates with alcohol dependence.[57]
Participation in mutual support groups, such as AA, is widely recommended both pre- and post-transplantation. It is reported that a combination of both pre- and post-LT addiction therapy is associated with a significant decrease in post-LT AR risk (p=0.002).[58] Mutual support programs provide the additional benefit of social support, which is less prominent in CBT and MI/MET.
Active participation is a typical requirement for listing in most transplant programs; however, it is important to consider the many barriers that may limit a patient’s ability to participate, including: (1) frequent hospital admissions related to decompensated liver disease; (2) decreased ability to engage meaningfully due to cognitive deficits; and (3) practical difficulties attending appointments, such as inability to drive resulting from encephalopathy or significant ascites-related volume overload.[59]
Conclusion
Alcohol recidivism remains a significant challenge post-LT, impacting long-term outcomes. The COVID-19 pandemic worsened alcohol use, contributing to higher ALD-related mortality and increased transplant demand. Early detection of high-risk patients and targeted interventions are essential for improving post-LT success. Strong psychosocial support and continuous follow-up can help reduce relapse risk. Policy changes should focus on individual patient risk rather than rigid sobriety timelines (i.e., 6-month rule). Accordingly, the level of therapeutic intervention should be customized for each LT recipient. Future strategies should incorporate integrated behavioral health, telehealth, and predictive modeling to enhance care. Future research should include prospective, multicenter studies with standardized relapse definitions and external validation of relapse risk–prediction tools across diverse settings. Transplant-specific trials and real-world comparative effectiveness studies are also needed to clarify the efficacy and long-term safety of MAUD and to optimize post-LT monitoring strategies.
Footnotes
How to cite this article: Elsawy M, Bardak AE, Yildiz E, Ozturk NB, Toruner MD, Gurakar M, et al. Prevention of alcohol relapse in post-liver transplant patients with alcohol use disorder. Hepatology Forum 2026; 7(4):407–415.
Ethics Committee Approval
Ethics committee approval was not required, as this study is a review article and did not involve human participants, animal subjects, or identifiable personal data.
Conflict of Interest
The authors declare no conflict of interest.
Financial Disclosure
This research received no external funding.
Use of AI for Writing Assistance
Artificial intelligence (AI)-assisted technologies (such as Large Language Models [LLMs], chatbots, or image creators) were not used in the production of submitted work.
Author Contributions
Concept: ME, AG; Design: ME, AEB, EY, MG, AG, MDT; Supervision: AG; Literature search: ME, AEB, EY, NBO, SAG, CC; Writing: ME, AEB, EY, NBO, MG, MDT; Critical review: MG, AG.
Peer-review
Externally peer-reviewed.
References
- 1.Lucey MR, Furuya KN, Foley DP. Liver Transplantation. N Engl J Med. 2023;389(20):1888–1900. doi: 10.1056/NEJMra2200923. [DOI] [PubMed] [Google Scholar]
- 2.Cholankeril G, Ahmed A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2018;16(8):1356–1358. doi: 10.1016/j.cgh.2017.11.045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.White AM, Castle IP, Powell PA, Hingson RW, Koob GF. Alcohol-related deaths during the COVID-19 pandemic. JAMA. 2022;327(17):1704–1706. doi: 10.1001/jama.2022.4308. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Lee BP, Dodge JL, Leventhal A, Terrault NA. Retail alcohol and tobacco sales during COVID-19. Ann Intern Med. 2021;174(7):1027–1029. doi: 10.7326/M20-7271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Rady ED, Anouti A, Mitchell MC, Cotter TG. Current clinical trials for alcohol-associated hepatitis. Am J Pathol. 2026;196(1):182–191. doi: 10.1016/j.ajpath.2025.03.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Moskatel LS, Slusky DJG. The impact of COVID-19 on alcohol sales and consumption in the United States: A retrospective, observational analysis. Alcohol. 2023;111:25–31. doi: 10.1016/j.alcohol.2023.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.National Institute on Alcohol Abuse and Alcoholism (NIAAA) Understanding alcohol use disorder. Available at: https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-use-disorder. Accessed: June 7, 2025.
- 8.Arab JP, Izzy M, Leggio L, Bataller R, Shah VH. Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. Nat Rev Gastroenterol Hepatol. 2022;19(1):45–59. doi: 10.1038/s41575-021-00527-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Van Melkebeke L, Korf H, Tsochatzis EA, van der Merwe S, Nevens F, Verbeek J. Treatment of severe alcoholic hepatitis: A systematic review. Curr Opin Pharmacol. 2021;60:91–101. doi: 10.1016/j.coph.2021.06.011. [DOI] [PubMed] [Google Scholar]
- 10.Jadaun SS, Saigal S. Post-transplant complications in alcohol-and metabolic-associated steatotic liver disease. Metab Target Organ Damage. 2025;5:1. doi: 10.20517/mtod.2025.73. [DOI] [Google Scholar]
- 11.Musto JA, Palmer G, Nemer M, Schell T, Waclawik G, Glover Q, et al. Early liver transplant for alcohol-associated liver disease has excellent survival but higher rates of harmful alcohol use. Clin Gastroenterol Hepatol. 2024;22(8):1646–1656.e2. doi: 10.1016/j.cgh.2024.04.025. [DOI] [PubMed] [Google Scholar]
- 12.Kodali S, Kaif M, Tariq R, Singal AK. Alcohol relapse after liver transplantation for alcoholic cirrhosis-impact on liver graft and patient survival: a meta-analysis. Alcohol Alcohol. 2018;53(2):166–172. doi: 10.1093/alcalc/agx098. [DOI] [PubMed] [Google Scholar]
- 13.Messinger JC, Hanto DW, Curry MP, Ladin K. Liver transplantation in alcohol-associated liver disease: ensuring equity through new processes. Liver Transpl. 2023;29(5):539–547. doi: 10.1097/LVT.0000000000000088. [DOI] [PubMed] [Google Scholar]
- 14.Addolorato G, Mirijello A, Barrio P, Gual A. Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol. 2016;65(3):618–630. doi: 10.1016/j.jhep.2016.04.029. [DOI] [PubMed] [Google Scholar]
- 15.World Health Organization International guide for monitoring alcohol consumption and related harm. World Health Organization. 2000. Available at: https://iris.who.int/handle/10665/66529. Accessed on June 5, 2025.
- 16.Erard-Poinsot D, Dharancy S, Hilleret MN, Faure S, Lamblin G, Chambon-Augoyard C, et al. Natural history of recurrent alcohol-related cirrhosis after liver transplantation: fast and furious. Liver Transpl. 2020;26(1):25–33. doi: 10.1002/lt.25647. [DOI] [PubMed] [Google Scholar]
- 17.Faure S, Herrero A, Jung B, Duny Y, Daures JP, Mura T, et al. Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication. J Hepatol. 2012;57(2):306–312. doi: 10.1016/j.jhep.2012.03.014. [DOI] [PubMed] [Google Scholar]
- 18.Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1790–1800. doi: 10.1056/NEJMoa1105703. [DOI] [PubMed] [Google Scholar]
- 19.Herrick-Reynolds KM, Punchhi G, Greenberg RS, Strauss AT, Boyarsky BJ, Weeks-Groh SR, et al. Evaluation of Early vs Standard Liver Transplant for Alcohol-Associated Liver Disease. JAMA Surg. 2021;156(11):1026–1034. doi: 10.1001/jamasurg.2021.3748. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Young K, Patel YA, Hoffman B, Peskoe S, Chow SC, Erhart K, et al. Alcohol relapse after liver transplantation: risk factors, outcomes, and a comparison of risk stratification models. Gastro Hep Adv. 2024;4(1):100550. doi: 10.1016/j.gastha.2024.09.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Legg K, Sparkes T, Booth I, Maluf D, Bhati C, Jakhete N, et al. Short-term alcohol abstinence prior to liver transplantation and impact on rejection. Journal of Liver Transplantation. 2024;16:100240. doi: 10.1016/j.liver.2024.100240. [DOI] [Google Scholar]
- 22.Schuckit MA. Alcohol-use disorders. Lancet. 2009;373(9662):492–501. doi: 10.1016/S0140-6736(09)60009-X. [DOI] [PubMed] [Google Scholar]
- 23.Marti-Aguado D, Gougol A, Gomez-Medina C, Jamali A, Abo-Zed A, Morales-Arraez D, et al. Prevalence and clinical impact of alcohol withdrawal syndrome in alcohol-associated hepatitis and the potential role of prophylaxis: a multinational, retrospective cohort study. EClinicalMedicine. 2023;61:102046. doi: 10.1016/j.eclinm.2023.102046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Attilia ML, Lattanzi B, Ledda R, Galli AM, Farcomeni A, Rotondo C, et al. The multidisciplinary support in preventing alcohol relapse after liver transplantation: A single-center experience. Clin Transplant. 2018;32(5):e13243. doi: 10.1111/ctr.13243. [DOI] [PubMed] [Google Scholar]
- 25.De Gottardi A, Spahr L, Gelez P, Morard I, Mentha G, Guillaud O, et al. A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years. Arch Intern Med. 2007;167(11):1183–1188. doi: 10.1001/archinte.167.11.1183. [DOI] [PubMed] [Google Scholar]
- 26.Gish RG, Lee A, Brooks L, Leung J, Lau JY, Moore DH., 2nd Long-term follow-up of patients diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver transplantation. Liver Transpl. 2001;7(7):581–7. doi: 10.1053/jlts.2001.25455. [DOI] [PubMed] [Google Scholar]
- 27.Maldonado J, Sher Y, Lolak S, Swendsen H, Skibola D, Neri E, et al. The Stanford integrated psychosocial assessment for transplantation: a prospective study of medical and psychosocial outcomes. Psychosomatic Medicine. 2015;77(9):1018–1030. doi: 10.1097/PSY.0000000000000241. [DOI] [PubMed] [Google Scholar]
- 28.Lee BP, Chen PH, Haugen C, Hernaez R, Gurakar A, Philosophe B, et al. Three-year results of a pilot program in early liver transplantation for severe alcoholic hepatitis. Ann Surg. 2017;265(1):20–29. doi: 10.1097/SLA.0000000000001831. [DOI] [PubMed] [Google Scholar]
- 29.Lee BP, Vittinghoff E, Hsu C, Han H, Therapondos G, Fix OK, et al. Predicting low risk for sustained alcohol use after early liver transplant for acute alcoholic hepatitis: the sustained alcohol use post-liver transplant score. Hepatology. 2019;69(4):1477–1487. doi: 10.1002/hep.30478. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Satapathy SK, Thornburgh C, Heda R, Jiang Y, Kedia SK, Nair SP, et al. Predicting harmful alcohol relapse after liver transplant: The HALT score. Clin Transplant. 2020;34(9):e14003. doi: 10.1111/ctr.14003. [DOI] [PubMed] [Google Scholar]
- 31.Weeks SR, Sun Z, McCaul ME, Zhu H, Anders RA, Philosophe B, et al. Liver transplantation for severe alcoholic hepatitis, updated lessons from the world’s largest series. J Am Coll Surg. 2018;226(4):549–557. doi: 10.1016/j.jamcollsurg.2017.12.044. [DOI] [PubMed] [Google Scholar]
- 32.Ting PS, Gurakar A, Wheatley J, Chander G, Cameron AM, Chen PH. Approaching alcohol use disorder after liver transplantation for acute alcoholic hepatitis. Clin Liver Dis. 2021;25(3):645–671. doi: 10.1016/j.cld.2021.03.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Schröck A, Thierauf-Emberger A, Schürch S, Weinmann W. Phosphatidylethanol (PEth) detected in blood for 3 to 12 days after single consumption of alcohol-a drinking study with 16 volunteers. Int J Legal Med. 2017;131(1):153–160. doi: 10.1007/s00414-016-1445-x. [DOI] [PubMed] [Google Scholar]
- 34.Andresen-Streichert H, Beres Y, Weinmann W, Schröck A, Müller A, Skopp G, et al. Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study. Transpl Int. 2017;30(6):611–620. doi: 10.1111/tri.12949. [DOI] [PubMed] [Google Scholar]
- 35.Kenan N, Larsson A, Axelsson O, Helander A. Changes in transferrin glycosylation during pregnancy may lead to false-positive carbohydrate-deficient transferrin (CDT) results in testing for riskful alcohol consumption. Clin Chim Acta. 2011;412(1-2):129–133. doi: 10.1016/j.cca.2010.09.022. [DOI] [PubMed] [Google Scholar]
- 36.Van Uytfanghe K, De Boosere E, Stove CP. Monitoring the use of alcohol-A critical overview of the state-of-the-art biomarkers. WIREs Forens Sci. 2022;4(5):e1457. doi: 10.1002/wfs2.1457. [DOI] [Google Scholar]
- 37.Staufer K, Andresen H, Vettorazzi E, Tobias N, Nashan B, Sterneck M. Urinary ethyl glucuronide as a novel screening tool in patients pre-and post-liver transplantation improves detection of alcohol consumption. Hepatology. 2011;54(5):1640–1649. doi: 10.1002/hep.24596. [DOI] [PubMed] [Google Scholar]
- 38.Bernstein EY, Baggett TP, Trivedi S, Herzig SJ, Anderson TS. Outcomes after initiation of medications for alcohol use disorder at hospital discharge. JAMA Netw Open. 2024;7(3):e243387. doi: 10.1001/jamanetworkopen.2024.3387. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Yaseen W, Mong J, Zipursky J. Sobering perspectives on the treatment of alcohol use disorder. JAMA Netw Open. 2024;7(3):e243340. doi: 10.1001/jamanetworkopen.2024.3340. [DOI] [PubMed] [Google Scholar]
- 40.Ayyala-Somayajula D, Bottyan T, Shaikh S, Lee BP, Cho SH, Dodge JL, et al. Safety of acamprosate for alcohol use disorder after liver transplant: A pilot randomized controlled trial. Liver Transpl. 2025;31(4):498–507. doi: 10.1097/LVT.0000000000000475. [DOI] [PubMed] [Google Scholar]
- 41.U.S. Food and Drug Administration Website VIVITROL® (naltrexone for extended-release injectable suspension) Intramuscular. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021897s015lbl.pdf. Accessed on Jun 20, 2025.
- 42.Díaz LA, Collier S, Yin J, Loomba R. Safety and tolerability of injectable extended-release naltrexone for the management of alcohol use disorder in advanced alcohol-associated liver disease. Aliment Pharmacol Ther. 2025;62(7):692–698. doi: 10.1111/apt.70237. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Ray LA, Bujarski S, Grodin E, Hartwell E, Green R, Venegas A, et al. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abuse. 2019;45(2):124–140. doi: 10.1080/00952990.2018.1528265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;2010(9):CD004332. doi: 10.1002/14651858.CD001867.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.NIH LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Available at: http://www.ncbi.nlm.nih.gov/books/NBK548103/. Accessed: June 20, 2025. [PubMed]
- 46.Garbutt JC, Kampov-Polevoy AB, Pedersen C, Stansbury M, Jordan R, Willing L, et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. Neuropsychopharmacology. 2021;46(13):2250–2256. doi: 10.1038/s41386-021-01055-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Colombo G, Agabio R, Carai MA, Lobina C, Pani M, Reali R, et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: I-Preclinical evidence. Alcohol Clin Exp Res. 2000;24(1):58–66. doi: 10.1111/j.1530-0277.2000.tb04554.x. [DOI] [PubMed] [Google Scholar]
- 48.Kumar A, Sharma A, Bansal PD, Bahetra M, Gill HK, Kumar R. A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian J Psychiatry. 2020;62(6):650–658. doi: 10.4103/psychiatry.IndianJPsychiatry_201_19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Farokhnia M, Tazare J, Pince CL, Bruns N, 6th, Gray JC, Lo Re V, 3rd, et al. Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. J Clin Invest. 2025;135(9):e188314. doi: 10.1172/JCI188314. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.John BV, Bastaich D, Marchetti D, Perumalswami P, Mustafa MZ, Dahman B, et al. Association of glucagon-like peptide-1 receptor agonists with liver-related outcomes and all-cause mortality in patients with harmful alcohol use: a target trial emulation study. Am J Gastroenterol. 2026;121(3):697–709. doi: 10.14309/ajg.0000000000003585. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395–405. doi: 10.1001/jamapsychiatry.2024.4789. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Lähteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry. 2025;82(1):94–98. doi: 10.1001/jamapsychiatry.2024.3599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.de Faria Moraes B, André Pedral Diniz Leite G, André Pedral Diniz Leite G, Silveira IB, Lana NV, Cançado GGL. Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis. Drug Alcohol Depend. 2025;275:112840. doi: 10.1016/j.drugalcdep.2025.112840. [DOI] [PubMed] [Google Scholar]
- 54.Schlagintweit HE, Lynch MJ, Hendershot CS. A review of behavioral alcohol interventions for transplant candidates and recipients with alcohol-related liver disease. Am J Transplant. 2019;19(10):2678–2685. doi: 10.1111/ajt.15569. [DOI] [PubMed] [Google Scholar]
- 55.Krist AH, Bradley KA. Addressing Alcohol Use. N Engl J Med. 2025;392(17):1721–1731. doi: 10.1056/NEJMcp2402121. [DOI] [PubMed] [Google Scholar]
- 56.Ting PS, Wheatley J, Chen PH. Behavioral treatment for patients with alcohol-related liver disease: a primer for hepatologists. Clin Liver Dis (Hoboken) 2020;15(1):31–35. doi: 10.1002/cld.854. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Weinrieb RM, Van Horn DH, Lynch KG, Lucey MR. A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation. Liver Transpl. 2011;17(5):539–547. doi: 10.1002/lt.22259. [DOI] [PubMed] [Google Scholar]
- 58.Ness C, Hardie K, Holbeck M, Saucedo-Crespo H, Auvenshine C, Steers J, et al. Integration of addiction treatment and behavioral therapies in comprehensive liver transplantation care to augment adherence and reduce alcohol relapse. J Liv Transpl. 2022;5:100061. doi: 10.1016/j.liver.2021.100061. [DOI] [Google Scholar]
- 59.Dienstag A, Dienstag P, Mohan K, Mirza O, Schubert E, Ford L, et al. An assessment of the psychosocial evaluation for early liver transplantation in patients with acute alcoholic hepatitis in the context of alcohol use disorder, a case-control study. Subst Abuse. 2022;16:11782218221115659. doi: 10.1177/11782218221115659. [DOI] [PMC free article] [PubMed] [Google Scholar]
